A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers

被引：0
|
作者：
Donghoon Shin
Yoon Jung Lee
Jihye Choi
Dahyoung Lee
Minjeong Park
Magdalena Petkova
机构：
[1] Samsung Bioepis Co.,Medical Affairs
[2] Ltd,Clinical Development
[3] Samsung Bioepis Co.,Biometrics
[4] Ltd,Clinical Bioanalysis
[5] Samsung Bioepis Co.,Clinical Pharmacology Unit
[6] Ltd,undefined
[7] Samsung Bioepis Co.,undefined
[8] Ltd,undefined
[9] SGS LSS,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
SB8; Bevacizumab; Biosimilar; Pharmacokinetics; Immunogenicity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：567 / 575
页数：8
相关论文
共 50 条
  • [41] Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers
    Chukwuani, CM
    Coker, HAB
    Oduola, AMJ
    Ifudu, ND
    Sowunmi, A
    CHEMOTHERAPY, 1998, 44 (06) : 369 - 376
  • [42] Rectal and sublingual administration of tacrolimus: a single-dose pharmacokinetic study in healthy volunteers
    Stifft, Frank
    Vanmolkot, Floris
    Scheffers, Ingrid
    van Bortel, Luc
    Neef, Cees
    Christiaans, Maarten
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (05) : 996 - 1004
  • [43] A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects
    Huang, Kai
    Que, Linling
    Ding, Ying
    Chu, Nannan
    Qian, Zhenzhong
    Shi, Yunfei
    Qin, Wei
    Li, Zhenni
    Chen, Yuanxin
    Gu, Xianghong
    Wang, Jiakun
    Zhang, Lin
    Zhang, Jisheng
    Zhu, Xiangyang
    Yang, Yongmin
    Tang, Yuan
    He, Qing
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [44] A randomized pharmacokinetic/pharmacodynamic study comparing the bioequivalence of potential biosimilar candidate P044 with reference medicine in healthy volunteers
    Raykova, Ekaterina
    Farahani, Mohammad Farmahini
    Ivanova, Stanislava
    Azhdarzadeh, Morteza
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (02) : 235 - 243
  • [45] A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab
    Demarchi, Martin
    Coliat, Pierre
    Barthelemy, Philippe
    Schott, Roland
    BenAbdelghani, Meher
    Kim, Michael
    Hii, Jocelyn Chung Shii
    Feyaerts, Peggy
    Ang, Felicia Rui Xia
    Derde, Marie Paule
    Deforce, Filip
    Petit, Thierry
    Schwabe, Chris
    Wynne, Chris
    Park, Lisa Soyeon
    Pivot, Xavier
    PLOS ONE, 2021, 16 (09):
  • [46] A randomized, double-blind, parallel-group, single-dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men
    Singh, Inderjeet
    Patel, Ronak
    Patel, Akash
    Jose, Vinu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (02) : 193 - 202
  • [47] Phase I, Single-Dose Study to Assess the Pharmacokinetics and Safety of Suramin in Healthy Chinese Volunteers
    Wu, Guolan
    Zhou, Huili
    Lv, Duo
    Zheng, Ruling
    Wu, Lihua
    Yu, Songxia
    Kai, Jiejing
    Xu, Nana
    Gu, Lie
    Hong, Nanfang
    Shentu, Jianzhong
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2023, 17 : 2051 - 2061
  • [48] Single-dose crossover pharmacokinetic/pharmacodynamic study of fospropofol vs propofol in healthy volunteers
    Shah, Ajit
    Fechner, Joerg
    Struys, Michel
    Mistry, Bipin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S455 - S456
  • [49] Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers
    Lissy, Michael
    Stiff, Dwight D.
    Kowalski, Mark M.
    Moore, Keith A.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (10) : 2423 - 2428
  • [50] A phase III study comparing BCD-021, a bevacizumab biosimilar, and reference bevacizumab in patients with stage IIIB or IV non-squamous NSCLC
    Fadeeva, N.
    Roy, B.
    Nagarkar, R.
    Adamchuk, H.
    Matrosova, M.
    Tjulandin, S.
    Stroyakovskiy, D.
    Zhuravleva, D.
    Voevodin, G.
    Shustova, M.
    Kryukov, K. A.
    Chistiakov, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S1022 - S1022
12345